natgillin/translations-raw huggingface dataset:
7 to 14 mg/kg (0.07 to
7 do 14 mg/kg (0,07 do 0,14 ml/kg) jedanput na dan
7 to 14 mg/kg once
7 do 14 mg/kg
7 to less than 13
7 do manje od 13
7 transdermal patches
7 transdermalnih flastera
7 transdermal patches of Leganto 4 mg/24 h 7 transdermal patches of Leganto 6 mg/24 h 7 transdermal patches of Leganto 8 mg/24 h
7 transdermalnih flastera Leganta 4 mg/24 h 7 transdermalnih flastera Leganta 6 mg/24 h 7 transdermalnih flastera Leganta 8 mg/24 h
7 transdermal patches of Neupro 4 mg/24 h 7 transdermal patches of Neupro 6 mg/24 h 7 transdermal patches of Neupro 8 mg/24 h
7 transdermalnih flastera Neupra 4 mg/24 h 7 transdermalnih flastera Neupra 6 mg/24 h 7 transdermalnih flastera Neupra 8 mg/24 h
7 transdermal patches.
7 transdermalnih flastera.
7 vials with 7 sterile 1 mL injection syringes with retractable injection needle and 14 alcohol swabs.
7 bočica sa 7 sterilnih štrcaljki za injekciju od 1 ml s iglom za injekciju na uvlačenje i 14 alkoholom natopljenih jastučića.
7 vials with powder for solution for injection.
7 bočica s praškom za otopinu za injekciju.
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● Ujedinjena Kraljevina
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● Ujedinjeno Kraljevstvo
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
7 Westferry Circus ●CanaryWharf●London E14 4HB ●United Kingdom
7 x 1 capsules (unit
7 x 1 kapsula
7 x 1 film-coated tablets
7 x 1 filmom obložena tableta
7 x 1 ml oral syringes.
7 oralnih štrcaljki x 1 ml.
7 x 1 tablet
7 x 1 tableta
7 x 1 tablet (unit dose)
7 x 1 tableta (jedinična doza)
7 x 1 tablets
7 x 1 tableta
7 x 3 ml oral syringes.
7 oralnih štrcaljki x 3 ml.
7 x 5 ml oral syringes.
7 oralnih štrcaljki x 5 ml.
7 yrs
7 godina
7% (2%)[0.6–4.4]
Djelomični
7% had an unknown metastatic status
7% s nepoznatim metastatskim statusom
7, 14, 28, 30, 50, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters
7, 14, 28, 30, 50, 84, 90 i 100 tableta u PVC/PVDC/aluminij blisterima ili u aluminijskim blisterima
7, 14, 28, 30, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters
7, 14, 28, 30, 84, 90 i 100 tableta u PVC/PVDC/aluminij blisterima ili u aluminijskim blisterima
7, 28 and 98 capsules
7, 28 i 98 kapsula
7, fig.
7, sl.
7, rue du Fer à Moulin – BP 09 F-75221 Paris Cedex 05 FRANCE
7, rue du Fer à Moulin – BP 09 F-75221 Paris Cedex 05 FRANCUSKA
7,000 IU/0.7 ml
7000 IU/0,7 ml
7,800 units*,
7800 jedinica*,
7-hydroxymetabolite: AUCinf: ↑ 29%
7-hidroksi metabolit: AUCinf: ↑ 29
7-ml vials of Type I hydrolytic glass containing 10, 50 or 100 doses of freeze-dried powder.
7-ml bočice od hidrolitičkog stakla tipa I koje sadrže 10, 50 ili 100 doza liofiliziranog praška.
7-valent Prevenar), as recommended by the WHO.
7-valentni Prevenar), prema preporukama SZO-a.
7.) If the average radiochemical purity is less than 95%, the preparation must not be administered.
7.) Ako je prosječna radiokemijska čistoća manja od 95 %, preparat se ne smije primijeniti.
7.0 mm, round, normal convex, white film-coated tablets debossed “OZ” over “2.5” on one side and “G” on the other side.
Okrugle, konveksne, bijele filmom obložene tablete veličine 7,0 mm, na kojima je s jedne strane utisnuta oznaka „OZ” iznad „2.5”, a s druge oznaka „G”.
7.0 years, EDSS score 2.0. In addition, 16% of patients had an EDSS score >3.5, 28% had ≥2 relapses in the prior year and 42% had previously received other approved MS treatments.
Osim toga, 16% bolesnika imalo je EDSS bodova > 3,5, 28% je imalo ≥ 2 relapsa u prethodnoj godini, a 42% je prethodno dobilo drugo odobreno liječenje za MS.
7.08 (4.34, 11.55) p<0.0001
7,08 (4,34; 11,55) p<0,0001
7.0a (6.8, 8.2)
7,0a (6,8; 8,2)
7.1% (-47.1% to 61.4%)
7,1% (-47,1% do 61,4%)
7.1% (95% CI: 0.9%, 13.2%)
7,1% (95% CI: 0,9%; 13,2%)
7.13
Ctrough
7.14mm round, white to off-white tablets debossed with ‘1MG’ on one side and ‘503’ on the other side.
Bijele do gotovo bijele, okrugle tablete, promjera 7,14 mm, s utisnutom oznakom ‘1MG’ na jednoj strani i ‘503’ na drugoj strani.
7.2 %) which, however normalises spontaneously.
7,2 %), koja se spontano normalizira.
7.2 (5.9, NR)
7,2 (5,9; ND)
7.2%) which, however normalises spontaneously.
7,2%), koja se, međutim, spontano normalizira.
7.3 (sham)
7,3 (placebo postupak)
7.3.1 Preparing for the injection
7.3.1 Priprema za injekciju
7.35 mg sodium per ml reconstituted solution (18.4 mg sodium per vial).
7,35 mg natrija po ml rekonstituirane otopine (18,4 mg natrija po bočici).
7.4% (95% CI: 0.7%, 14.2%)
7,4% (95% CI: 0,7%; 14,2%)
7.4% (95% CI: 2.5%, 12.3%)
7,4% (95% CI: (2,5%; 12,3%))
7.4% (95% CI: 2.5%, 12.3%)
7,4% (95% CI: 2,5%; 12,3%)
7.4%)a, b
(-5,1 %; 7,4 %)a, b
7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p = 0.017
7,5 događaja/1000 bolesnik-godini, dijeta sama 12,7 događaja/1,000 bolesnik-godini, p=0,017
7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017,
7,5 događaja/1000 bolesnik-godina, samo dijeta 12,7 događaja/1000 bolesnik-godina, p=0,017,
7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017;
7,5 događaja/1000 bolesnik-godina, samo dijeta 12,7 događaja/1000 bolesnik-godina, p=0,017;
7.5 hours from the time of calibration
7,5 sati od sata kalibriranja.
7.5 mg fondaparinux sodium in 0.6 ml solution for injection
7,5 mg fondaparinuksnatrija u 0,6 ml otopine za injekcije
7.5 mg once a day
7,5 mg jednom na dan
7.5 mg once daily2
7,5 mg jednom dnevno2
7.5 mg once daily2
7,5 mg jednom dnevno2, 3
7.5 mg/kg every 24 hours
7,5 mg/kg svakih 24 sata
7.5 mg/kg IV 30-90 mins
7,5 mg/kg i.v./30 – 90 min
7.5 ml of reconstituted solution contains 15 mg of verteporfin.
7,5 ml pripremljene otopine sadrži 15 mg verteporfina.
7.5 ml oseltamivir suspension delivers 1.3 g of sorbitol.
7,5 ml oseltamivir suspenzije sadrži 1,3 g sorbitola.
7.5 to < 15
13 do <15
7.5 to < 15
7,5 do <15
7.5.1 Symbols printed on the administration system
7.5.1 Simboli otisnuti na sustavu za primjenu
7.6 (2.1-18.0), and 4.0 (1.5-6.6) μg/ml, respectively.
4,0 (1,5-6,6) μg/ml.
7.6 (6.7 to 12.6)
7,6 (6,7 do 12,6)
7.6 Technical characteristics
7.6 Tehničke značajke
7.67 mg methyl parahydroxybenzoate (E218)
7,67 mg metil-parahidroksibenzoata (E218) 0,85 mg propil-parahidroksibenzoata (E216)
7.7 mg pyriproxifen, 635 mg permethrin
7.7 mg piriproksifena, 635 mg permetrina
7.7, 12.1
interferon alfa/ribavirin
7.8 (6.9, 9.5)d
7,8 (6,9; 9,5)d
7.8 (7.1, NE)
7,8 (7,1, NP)
7.8 ± 6.41
Vremenska točka procjene
7.8. Further dilution is required.
Otopina se mora dodatno razrijediti.
7.9 months for patients treated with docetaxel (ITT N = 288).
Intent-To-Treat [ITT], N=283), a u bolesnika liječenih docetakselom 7,9 mjeseci (ITT populacija, N = 288).
7.91
(n=128)
7.93
(n=203)
7.94mm round, green tablets debossed with ‘3MG’ on one side and ‘503’ on the other side.
Zelene, okrugle tablete, promjera 7,94 mm, s utisnutom oznakom ‘3MG’ na jednoj strani i ‘503’ na drugoj strani.
7/11 patients in the full analysis set achieved Radiographic Global Impression of Change scores of +2 at Week 24 compared to baseline radiographs.
U cijeloj skupini za analizu, 7/11 bolesnika postiglo je rezultat na ljestvici za procjenu općeg radiografskog dojma promjene od +2 u 24. tjednu u usporedbi s rendgenskim snimkama na početku.
70 (2 x 35)
70 (2 x 35) tableta
70 (2 x 35) tablets
70 (2 x 35) tableta
70 avenue du Général de Gaulle F – 92800 Puteaux
70 avenue du Général de Gaulle F-92800 Puteaux
70 avenue du Général de Gaulle F-92800 Puteaux
70 avenue du Général de Gaulle F – 92800 Puteaux
70 capsules
70 kapsula
70 coated tablets
70 obloženih tableta
70 doctor if they do not disappear after a few weeks.
Ako ne nestanu nakon nekoliko tjedana, posjetite liječnika.
70 film-coated tablets 28 x 1 film-coated tablets
Multipakiranje sa 70 (2 pakiranja od 35) filmom obloženih tableta
70 hard capsules
70 tvrdih kapsula
70 mg (from two 50 mg vials)**
70 mg (iz dvije bočice od 50 mg)
70 mg (from two 50-mg vials)**
70 mg (iz dvije bočice od 50 mg)
70 percent improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores compared with placebo at week 24.
Bath Ankylosing Spondylitis Disease Activity Indeks) u usporedbi s placebo skupinom u 24. tjednu.
70 point response is defined as reduction in CDAI score by at least 70 points
Odgovor od 70 bodova definiran je kao smanjenje CDAI skora za barem 70 bodova
70 Point Response, week 3
Odgovor od 70 bodova, 3. tjedan
70 Point Response, week 6
Odgovor od 70 bodova, 6. tjedan
70 tablets
70 tabeta
70 to 80
70 do 80
70 x (90-15) x 0.5 = 2,625 IU.
70 x (90-15) x 0,5 = 2625 IU.
70 x 1 film-coated tablets
70 x 1 filmom obložena tableta
70 x 1 hard capsules.
70 x 1 tvrda kapsula.
70 x 1, 98 or 98 x 1 film-coated tablets per carton.
70, 70 x 1, 98 ili 98 x 1 filmom obloženih tableta.
70%, and preferably also include PFS2, or, at least, time on next therapy.
70%, te po mogućnosti također uključiti drugo preživljenje bez progresije ili barem vrijeme na slijedećoj terapiji.
70%; P < .0001
70%; P < 0,0001
70, avenue du General de Gaulle F-92 800 Puteaux
70 Avenue du General de Gaulle F-92 800 Puteaux
70, avenue du Général de Gaulle F- 92800 Puteaux
70 avenue du Général de Gaulle F- 92800 Puteaux,
70, avenue du Général de Gaulle F- 92800 Puteaux
70 Avenue du Général de Gaulle F-92800 Puteaux
70, avenue du Général de Gaulle F- 92800 Puteaux,
70 avenue du Général de Gaulle F- 92800 Puteaux,
70.6 (49.0-NA)
(49,0-NP)
70.6 (49.0-NA)
70,6 (49,0-NP)
70.77 mg) of sodium and should be taken into consideration for patients on a controlled sodium diet.
To treba uzeti u obzir u bolesnika koji su na režimu prehrane s ograničenim unosom natrija.
700 mg (1 tablet or 14 ml suspension)
700 mg (1 tableta ili 14 ml suspenzije)
700 mg/100 mg BID
Fosamprenavir/ritonavir 700 mg/100 mg
700/100 mg twice daily), and the interaction was assessed under steady- state conditions where drugs were administered for 10 to 21 days,
700/100 mg 2 puta dnevno), a interakcije su procijenjene u uvjetima stanja dinamičke ravnoteže kada su lijekovi primjenjivani tijekom razdoblja od 10 do 21 dan.
700/100 mg twice daily), and the interaction was assessed under steady- state conditions where drugs were administered for 10 to 21 days.
700/100 mg 2 puta dnevno), a interakcije su procijenjene u uvjetima stanja dinamičke ravnoteže kada su lijekovi primjenjivani tijekom razdoblja od 10 do 21 dan.
7000 IU/0.7 ml
6000 IU/0,6 ml
7000 IU/0.7 ml
7000 IU/0,7 ml
7000 microgram (mcg/ml) for patients >2 years of age with a BSA of ≤1.3
7000 mikrograma (μg/ml) za bolesnike >2 godine starosti s površinom tijela ≤1,3
71%; P < .0001 73%; P < .0001
71%; P < 0,0001 73%; P < 0,0001
71.0 months
71,0 mjesec
71.2% vs 47.3%
43,0% vs 32,2
71.4% (20/28)c
71,4% (20/28)c
72 hours be co-administered with Stribild.
10 mg u 72 sata se smije primijeniti istovremeno sa Stribildom.
72 hours; vardenafil should be used
72 sata; vardenafil treba
72 or 48 Weeks
72 ili 48 tjedana
72 spot-on applicators
72 aplikatora za nakapavanje
72 Weeks
72 tjedna
72 x serum creatinine (mg/dl)
72 x kreatinin u serumu (mg/dl)
72% of patients were never smokers, 99% of patients had a World Health Organization (WHO) performance status of 0 or 1 and 39% of patients had brain metastases (stable for at least 4 weeks and not requiring corticosteroids).
72% bolesnika nisu nikada pušili, 99% bolesnika je imalo WHO (World Health Organization) izvedbeni status od 0 ili 1, te je 39% bolesnika imalo metastaze u mozgu (stabilni tijekom najmanje 4 tjedna i nije bila potrebna primjena kortikosteroida).
72.4 (66.6 to -)
72,4 (66,6 do -)
72.7 (61.3 to
72,7 (61,3 do
726/2004, the MAH shall complete, within the stated timeframe, the following measures:
726/2004, nositelj odobrenja će, unutar navedenog vremenskog okvira, dovršiti sljedeće mjere:
728 patients received catumaxomab intraperitoneally, 293 patients as 6 hour - and 435 patients as 3 hour infusions.
728 bolesnika primilo je katumaksomab intraperitonealno, 293 bolesnika u obliku infuzije u trajanju od 6 sati i 435 bolesnika u obliku infuzije u trajanju od 3 sata.
73% (36/49)
T12/PR24
73% of patients enrolled in Psoriasis Studies I and II had received prior systemic therapy or phototherapy.
U ispitivanjima Psoriasis Study I i II73% uključenih bolesnika prethodno je primalo sistemsku terapiju ili fototerapiju.
73% – 95% of the daily dose of total radioactivity was recovered from the faeces.
Iz fecesa je oporavljeno 73 % do 95 % dnevne doze ukupne radioaktivnosti.
73%, p<.0021
73%, p<0,0021
73%; P < .0001
73%; P < 0,0001
73042 Casarano (LE) - Italy
73042 Casarano (LE) - Italija
73614 Schorndorf Germany
73614 Schorndorf Njemačka
74% (398/540) (70%, 77%)b
44% (38/87)
74540 Alby-sur-Chéran France
74540 Alby-sur-Chéran Francuska
74770 Opava-Komarov Czech Republic
74770 Opava-Komarov Češka
74770 Opava-Komárov Czech Republic
74770 Opava-Komárov Češka
75 % of previous dose (both ALIMTA and cisplatin )
75% prethodne doze (i lijeka ALIMTA i cisplatina)
75 % of previous dose (both Pemetrexed Lilly and cisplatin )
75% prethodne doze (i lijeka Pemetrexed Lilly i cisplatina)
75 IU
Put primjene
75 IU (150 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
75 IU (150 IU/ml) aktivnosti rekombinantnog folikulostimulirajućeg hormona (FSH).
75 kg patient is initiated at 1 µg/kg of romiplostim.
Kod bolesnika s težinom 75 kg se započinje s 1 µg/kg romiplostima.
75 mcg/0.3 ml
75 mcg/0,3 ml
75 mg 13C-
Posudicu
75 mg can be made up of a 30 mg capsule plus a 45 mg capsule
75 mg se može dobiti uzimanjem jedne kapsule od 30 mg i jedne kapsule od 45 mg
75 mg dose — 3 sachets
Doza od 75 mg — 3 vrećice
75 mg doses can be administered as either
Doze od 75 mg mogu se primijeniti kao:
75 mg doses can be administered as either:
Doze od 75 mg mogu se primijeniti kao:
75 mg film-coated tablets
75 mg filmom obložene tablete
75 mg film-coated tablets Clopidogrel
75 mg filmom obložene tablete klopidogrel
75 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172).
75 mg filmom obložene tablete: poli(vinilni) alkohol, titanijev dioksid (E171), makrogol 3350, talk, žuti željezov oksid (E172), crveni željezov oksid (E172), crni željezov oksid (E172)
75 mg granules taken orally every 12 hours with fat-containing food
75 mg granule, uzimaju se peroralno svakih 12 sati s hranom koja sadrži masti
75 mg is made up of a 30 mg dose plus a 45 mg dose
75 mg se može dobiti uzimanjem jedne doze od 30 mg i jedne doze od 45 mg
75 mg IV/100 mg SC N=538
75 mg i.v./100 mg s.c.
75 mg oseltamivir suspension delivers 2.1 g of sorbitol.
75 mg oseltamivir suspenzije sadrži 2,1 g sorbitola.
75 mg q12h
75 mg svakih 12 sati
75 mg suspension for injection
75 mg suspenzija za injekciju
75 mg/kg feed) for 10 days improved the clinical condition of the pigs, reduced diarrhoea and improved productivity.
75 mg/kg/hrane) tijekom 10 dana poboljšao je kliničko stanje svinja, smanjio proljev i poboljšao produktivnost.
75 mg/kg feed) for at least 7 days successfully treated swine dysentery.
75 mg/kg hrane) tijekom najmanje 7 dana uspješno je liječilo svinjsku dizenteriju.
75 mg/ml solution for injection
Otopina za injekciju od 75 mg/ml
75 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 75 mikrograma
75 to 100
75 do 100
75 to 121
75 do 121
75 years did not identify age as significantly influencing entecavir pharmacokinetics.
Analiza populacijske farmakokinetike u bolesnika u dobi od 16 do 75 godina nije pokazala da je dob značajno utjecala na farmakokinetiku entekavira.
75 yrs
75 godina
75% dose reduction
Smanjenje doze za 75
75% of previous dose (both Pemetrexed Hospira and cisplatin)
75% prethodne doze (i lijeka Pemetreksed Hospira i cisplatina)
75% of the dose recovered within 96 hours.
U roku od 96 sati nađeno je 75% doze.
75) at week 13
< 75) u 13. tjednu
75-90 minutes (ml/hr)
75-90 minuta (ml/sat)
75.6 micrograms
75,6 mikrograma
75.9 %
kopije/ml)
750 mg every 8 hours
1 mg jedanput dnevno
750 mg every 8 hours
750 mg svakih 8 sati
750 mg film-coated tablets: iron oxide yellow (E172), iron oxide red (E172) and sunset yellow FCF (E110).
750 mg filmom obložene tablete: žuti željezov oksid (E 172), crveni željezov oksid (E172) i sunset yellow FCF (E110).
750 mg tablet: Indigo carmine (E132), sunset yellow (E110), iron oxide red (E172).
750 mg tableta: indigo carmine (E132), sunset yellow (E110), crveni željezov oksid (E 172).
750 mg tablet: indigo carmine aluminium lake (E132), sunset yellow FCF aluminium lake (E110) 1000 mg tablet: (no additional colourant).
750 mg tableta: indigo carmine aluminium lake (E132), sunset yellow FCF aluminium lake (E110) 1000 mg tableta: (nema dodatnih bojila).
750 mg tablet: sunset yellow FCF (E110), iron oxide red (E172)
750 mg tableta: sunset yellow FCF (E110), crveni željezov oksid (E 172)
750 mg: 20, 30, 50, 60, 80, 100 x 1, 100 film-coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets
750 mg: 20, 30, 50, 60, 80, 100 x 1, 100 filmom obloženih tableta i višestruka pakiranja koja sadrže 200 (2 pakiranja od 100) filmom obloženih tableta
750 mg: 20, 30, 50, 60, 80, 100, 120 and multipack of 200 (2 packs of 100) film-coated tablets.
750 mg: 20, 30, 50, 60, 80, 100, 120 i višestruka pakiranja od 200 (2 pakiranja od 100) filmom obloženih tableta.
750 mg: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, iron oxide red (E172), sunset yellow FCF(E110)
750 mg: poli(vinilni alkohol), titanijev dioksid (E171), makrogol, talk, crveni željezov oksid (E 172), sunset yellow FCF (E110)
75002 Paris France
75002 Pariz Francuska
75003 Paris France
75003 Pariz Francuska
75223 Niefern-Öschelbronn GERMANY
75223 Niefern-Öschelbronn NJEMAČKA‌
75223 Niefern-Öschelbronn Germany
75223 Niefern-Öschelbronn Njemačka
75237 Uppsala Sweden
75237 Uppsala ŠVEDSKA
754) with a hazard ratio of 0.61 (95% CI 0.56; 0.66).
17,0) s omjerom hazarda od 0,61 (95% CI 0,56; 0,66).
75th Percentile Overall Survival (months)
75. percentil sveukupnog preživljenja (mjeseci)
76 cases of thrombocytopenia were detected.
Prijavljeno je 76 slučajeva trombocitopenije.
76% NA
76% ND
76%; P < .0001 77%; P < .0001
76%; P < 0,0001 77%; P < 0,0001
76%§ NA
76%§ ND
76, D-35041 Marburg Germany
76, D-35041 Marburg Njemačka
76.5 (68.5,
N/Pc
76505 Saue Estonia
76505 Saue Estonija
76580 Le Trait France
76580 Le Trait Francuska
76960 Notre Dame de Bondeville France
76960 Notre Dame de Bondeville Francuska
77%; P < .0001
77%; P < 0,0001
78 g/day.
78 g/dan.
78.7 %
(18,1; NP)
78440 Porcheville France
78440 Porcheville Francuska
79%; P < .0001
79%; P < 0,0001
79.1)
N/D
79090 Freiburg Germany
79090 Freiburg Njemačka
79539 Lorrach GERMANY
79539 Lorrach NJEMAČKA
79539 Lörrach Germany
79539 Lörrach Njemačka
79639 Grenzach-Wyhlen GERMANY
79639 Grenzach-Wyhlen NJEMAČKA
79639 Grenzach-Wyhlen Germany
D-79639 Grenzach-Wyhlen Njemačka
79639 Grenzach-Wyhlen, Germany.
79639 Grenzach-Wyhlen Njemačka
79639 Grenzach-Wyhlen, Germany.
79639 Grenzach-Wyhlen, Njemačka.
7A Târgu Mureş 540472 Romania
7A Târgu Mureş 540472 Rumunjska
7A, RO-540472 Targu-Mures Romania
7A, RO-540472 Targu-Mures Rumunjska
7In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
7 U kliničkim ispitivanjima pioglitazona, incidencija povišenja ALT-a za više od tri puta iznad gornje granice normale bila je jednaka onoj uz placebo, ali manja od one opažene u skupinama koje su kao usporedni lijek primale metformin ili sulfonilureju.
7th nerve paralysis, dizziness
paraliza 7. živca, omaglica
8 (1 x 8) capsules (blister unit + 1 Turbospin powder inhaler
8 (1 x 8) kapsula (blister jedinica) + 1 Turbospin inhalator za prašak
8 - 24 hours until adequate wound healing, then continue therapy for at least another 7 days to maintain a FVIII activity of 30 % - 60 % (IU/dl).
postigne odgovarajuće cijeljenje rane, a potom nastavite s liječenjem tijekom najmanje 7 dodatnih dana kako biste održali aktivnost FVIII od 30% do 60%.
8 000 IU/0.8 ml
8000 IU/0,8 ml
8 AM
8 h
8 capsules
8 kapsula
8 capsules
8 kapsula 12 kapsula 59,5 ml
8 cartridges
6 uložaka
8 cartridges of 3ml.
8 uložaka od 3 ml.
8 cleansing swabs;
8 tupfera za čišćenje
8 cycles.
8 ciklusa.
8 days from the date of ART (= end of production).
8 dana od datuma vremena umjeravanja aktivnosti (= kraja proizvodnje).
8 EXPIRY DATE
8 ROK VALJANOSTI
8 Falls were more common in the elderly (≥ 65 years old)
8 Padovi su bili češći u starijih osoba (≥ 65 godina)
8 Falls were more common in the elderly (≥65 years old)
8 Padovi su bili češći u starijih osoba (≥ 65 godina)
8 Falls were more common in the elderly (≥65 years old).
8 Padovi su bili češći u starijih osoba (≥ 65 godina starosti)
8 Falls were more common in the elderly (≥65 years old).
8 Padovi su bili češći u starijih osoba (≥ 65 godina)
8 hard capsules and one Turbospin inhaler device sufficient for 4 days use.
8 tvrdih kapsula i jedan inhalator za prašak Turbospin, što je dovoljno za 4 dana primjene.
8 hours (including infusion time) after dilution when stored at 20 °C  5 °C
8 sati (uključujući vrijeme infuzije) nakon razrjeđivanja ako se čuva na temperaturi od 20 °C  5 °C
8 hours (including infusion time) after dilution when stored at 25°C ± 2°C
8 sati (uključujući vrijeme infuzije) nakon razrjeđivanja ako se čuva na temperaturi od 25°C ± 2°C
8 hours)/ Rilpivirine
8 sati)/rilpivirin
8 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 - 3 kg over one year.
8 U ispitivanjima kontroliranima aktivnim komparatorom, srednja vrijednost povećanja tjelesne težine monoterapijom pioglitazonom iznosila je 2-3 kg tijekom jedne godine.
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30 % of olanzapine treated patients with normal baseline prolactin value.
8 U kliničkim ispitivanjima u trajanju do 12 tjedana koncentracije prolaktina u plazmi prelazile su gornju granicu normalnog raspona u približno 30% bolesnika liječenih olanzapinom s normalnom početnom vrijednošću prolaktina.
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value.
8 U kliničkim ispitivanjima u trajanju do 12 tjedana koncentracije prolaktina u plazmi prelazile su gornju granicu normalnog raspona u približno 30 % bolesnika liječenih olanzapinom s normalnom početnom vrijednosti prolaktina.
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value.
8 U kliničkim ispitivanjima u trajanju do 12 tjedana, koncentracije prolaktina u plazmi prelazile su gornju granicu normalnog raspona u približno 30 % bolesnika liječenih olanzapinom s normalnom početnom vrijednosti prolaktina.
8 injection needles
8 igala za injekciju
8 kg to less than 10 kg
8 kg do manje od 10 kg
8 kg to less than 10 kg
od 8 kg do manje od 10 kg
8 kg x 3mg per kg = 24 mg
8 kg x 3 mg po kg = 24 mg
8 March 2002 / 20 February 2007
8. ožujka 2002./20. veljače 2007.
8 Mean HbA1c change is the difference between the saxagliptin+metformin and metformin alone groups.
8 Prosječna promjena vrijednosti HbA1c odnosi se na razliku između skupine koja je primala saksagliptin+metformin i skupine koja je primala samo metformin.
8 mg cimicoxib 30 mg cimicoxib
8 mg cimikoksib 30 mg cimikoksib
8 mg fluoxetine (as 9.04 mg fluoxetine hydrochloride) 16mg fluoxetine (as 18.08mg fluoxetine hydrochloride) 32 mg fluoxetine (as 36.16 mg fluoxetine hydrochloride) 64 mg fluoxetine (as 72.34 mg fluoxetine hydrochloride)
8 mg fluoksetina (kao 9,04 mg fluoksetin-hidroklorida) 16 mg fluoksetina (kao 18,08 mg fluoksetin-hidroklorida) 32 mg fluoksetina (kao 36,16 mg fluoksetin-hidroklorida) 64 mg fluoksetina (kao 72,34 mg fluoksetin-hidroklorida)
8 mg fluoxetine (as fluoxetine hydrochloride)
8 mg fluoksetina (kao 9,04 mg fluoksetin-hidroklorid)